<DOC>
	<DOCNO>NCT00087152</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth tumor cell block enzymes necessary growth . Drugs use chemotherapy , capecitabine , work different way stop tumor cell divide stop grow die . Combining imatinib mesylate capecitabine may kill tumor cell . PURPOSE : This phase II trial study well give imatinib mesylate together capecitabine work treat woman progressive stage IV breast cancer .</brief_summary>
	<brief_title>S0338 , Imatinib Mesylate Capecitabine Treating Women With Progressive Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine confirm complete partial response rate woman progressive stage IV adenocarcinoma breast treat imatinib mesylate capecitabine . - Determine 6-month progression-free survival patient treat regimen . - Determine toxicity regimen patient . - Correlate , preliminarily , c-kit platelet-derived growth factor receptor expression estrogen progesterone receptor status , response , survival , time disease progression patient treat regimen . OUTLINE : This multicenter study . Patients receive oral imatinib mesylate* daily day 1-21 oral capecitabine twice daily day 1-14 . Courses repeat every 21 day absence disease progression unacceptable toxicity . NOTE : *If patient tolerates start dose imatinib mesylate course 1 , dose increase subsequent course . Patients follow every 6 month 3 year . PROJECTED ACCRUAL : A total 25-70 patient ( 25-45 patient measurable disease 25 non-measurable disease ) accrue study within 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma breast Stage IV measurable disease Disease progression least 1 , 2 , prior chemotherapy regimens metastatic disease Patients hormonesensitive tumor must receive prior hormonal therapy Patients human epidermal growth factor receptor 2 ( HER2 ) /neuoverexpressing tumor ( 3+ immunohistochemistry amplify fluorescent situ hybridization ) receive trastuzumab ( HerceptinÂ® ) adjuvant metastatic setting ( unless contraindicate ) No clinical evidence know brain central nervous system ( CNS ) disease Hormone Receptor status know Female age 18 Performance status Zubrod 02 Absolute neutrophil count &gt; 1,500/mm^3 Leukocyte count &gt; 3,000/mm^3 Platelet count &gt; 100,000/mm^3 Bilirubin normal aspartate aminotransferase ( AST ) / alanine aminotransferase ( ALT ) &lt; 2.5 time upper limit normal Creatinine normal OR Creatinine clearance &gt; 60 mL/min Not pregnant nursing Fertile patient must use effective contraception 3 month study participation No history severe hypersensitivity reaction compound similar chemical biological composition imatinib mesylate , capecitabine , fluorouracil No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No prior biologic therapy ( e.g. , vaccine ) No concurrent filgrastim ( GCSF ) chemotherapyinduced neutropenia No prior capecitabine fluorouracil metastatic breast cancer Prior hormonal therapy allow More 4 week since prior radiotherapy Previously irradiate area ( ) must site disease More 4 week since prior major surgery More 4 week since prior therapy breast cancer No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational commercial agent therapy metastatic breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>